Vertex Pharmaceuticals announced a deal to buy Semma Therapeutics, which focuses on using stem cell-derived human islets as a possible cure for type 1 diabetes.

Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.

There is a ban on conducting experiments on real human embryos after 14 days of growth, and researchers at Rockefeller University appear to have found a way to work around that ethical limitation.

Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.

The Allen Institute for Cell Science launched the Integrated Mitotic Stem Cell, a new tool that visualizes mitosis.

U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.

The CEO of Platelet BioGenesis sees a future in the development of an on-demand platelet product made from stem cells.

BrainStorm Cell Therapeutics Inc. received approval from the U.S. Food and Drug Administration to begin a clinical trial of the company’s experimental stem cell treatment in patients with progressive multiple sclerosis.

In the wake of a significant number of journal articles being retracted due to falsified data, the National Heart, Lung, and Blood Institute – part of the National Institutes of Health – is halting a clinical trial that is testing an experimental stem cell therapy for heart patients.

CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.